Analyst Rating Update on Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) : 12 analysts are covering Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and their average rating on the stock is 1, which is read as a Strong Buy. 12 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) : The consensus price target for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is $190.36 for the short term with a standard deviation of $15.88. The most optimist securities analyst among the 11 who monitor the stock believes that the stock can reach $210, however, the pessimist price target for the company is $155.

For the current week, the company shares have a recommendation consensus of Buy. Also, Goldman Sachs initiates coverage on Jazz Pharmaceuticals plc (NASDAQ:JAZZ). In the latest research report, Goldman Sachs announces the target price to $196 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on June 6, 2016.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ): stock turned positive on Tuesday. Though the stock opened at $134.95, the bulls momentum made the stock top out at $137.545 level for the day. The stock recorded a low of $133.38 and closed the trading day at $137.07, in the green by 3.36%. The total traded volume for the day was 901,904. The stock had closed at $132.61 in the previous days trading.

In an insider trading activity, The officer (SVP, US Commercial), of Jazz Pharmaceuticals Plc, Miller Michael Patrick had unloaded 100 shares at $149.64 per share in a transaction on June 15, 2016. The total value of transaction was $14,964. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.